Cost-Minimization and Budget Impact Analysis of Certolizumab Pegol for Patients With Crohn’s Disease, Moderate or Severe, With Relapse After Conventional Treatment From the Perspective of the Brazilian Private Payer

Jornal Brasileiro de Economia da Saúde

doi 10.21115/jbes.v9.n1.p44-53